GlaxoSmithKline FY10 net profit up 10.37 pc to Rs 560.57 cr
GlaxoSmithKline Pharmaceuticals today said its consolidated net profit rose by 10.37 per cent to Rs 560.57 crore for the year ended December 31, 2010.
By PTI |
NEW DELHI: GlaxoSmithKline Pharmaceuticals today said its consolidated net profit rose by 10.37 per cent to Rs 560.57 crore for the year ended December 31, 2010.
The company had posted a net profit of Rs 507.86 crore for the January-December, 2009 period, GlaxoSmithKline Pharmaceuticals said in a statement.
Net sales of the company rose to Rs 2,151.05 crore for the year ended December 31, 2010, from Rs 1,907.77 crore in the same period of the previous calendar year.
The company's board of director recommended a dividend of Rs 40 per share for the year ended December 31, 2010, in its meeting today.
"Our mass markets and mass speciality businesses have registered good growths, aided by launch of branded generics, increasing extension of rural coverage and focused efforts in the hospital segment," GlaxoSmithKline Pharma MD B Joshipura said.
The company's sales performance was supported by all its business units; mass markets, mass speciality, specialities including dermatological, oncology, critical care and vaccines, it said.
During the year, the company launched Mycamine, an injectible antifungal in-licensed from Astellas, and Parit D capsules, in-licensed from Esai.
Shares of GlaxoSmithKline Pharma today closed at Rs 2,201.80 on the Bombay Stock Exchange, down 0.37 per cent from its previous close.
The company had posted a net profit of Rs 507.86 crore for the January-December, 2009 period, GlaxoSmithKline Pharmaceuticals said in a statement.
Net sales of the company rose to Rs 2,151.05 crore for the year ended December 31, 2010, from Rs 1,907.77 crore in the same period of the previous calendar year.
The company's board of director recommended a dividend of Rs 40 per share for the year ended December 31, 2010, in its meeting today.
"Our mass markets and mass speciality businesses have registered good growths, aided by launch of branded generics, increasing extension of rural coverage and focused efforts in the hospital segment," GlaxoSmithKline Pharma MD B Joshipura said.
The company's sales performance was supported by all its business units; mass markets, mass speciality, specialities including dermatological, oncology, critical care and vaccines, it said.
ADVERTISEMENT
During the year, the company launched Mycamine, an injectible antifungal in-licensed from Astellas, and Parit D capsules, in-licensed from Esai.
Shares of GlaxoSmithKline Pharma today closed at Rs 2,201.80 on the Bombay Stock Exchange, down 0.37 per cent from its previous close.
Too busy to trade in stocks? Invest in Mutual Funds with ET Money!
Bookmark or read stories offline -
Download ET Markets APP
Download ET Markets APP
ADVERTISEMENT
